entrectinib sold brand name rozlytrek anticancer medication used treat nonsmall cell lung cancer ntrk fusionpositive solid selective tyrosine kinase inhibitor tki tropomyosin receptor kinases trk b c cros oncogene anaplastic lymphoma kinase common side effects include tiredness constipation dysgeusia taste disturbances edema swelling fluid retention dizziness diarrhea nausea feeling sick dysesthesia unpleasant abnormal feeling touched dyspnea difficulty breathing anemia low red blood cell count increased weight increased blood creatinine possible sign kidney problems pain cognitive disorders problems ability think learn remember vomiting cough approved medical use united states august australia may european union july us entrectinib indicated treat patients whose cancers specific genetic feature used solid tumors entrectinib approved use less twelve years european union entrectinib monotherapy indicated treatment adults adolescents twelve years age older solid tumours expressing neurotrophic tyrosine receptor kinase ntrk gene also indicated treatment adults positive advanced non small cell lung cancer nsclc previously treated common side effects entrectinib include fatigue constipation dysgeusia edema dizziness diarrhea nausea dysesthesia dyspnea myalgia cognitive impairment weight gain cough vomiting fever arthralgia vision serious side effects entrectinib congestive heart failure central nervous system effects skeletal fractures hepatotoxicity hyperuricemia qt prolongation vision us entrectinib orphan drug designation rare pediatric disease designation treatment neuroblastoma orphan drug designation treatment trka trkb trkc alkpositive nonsmall cell lung cancer nsclc metastatic colorectal cancer verification eu orphan designation fda approved entrectinib people metastatic nonsmall cell lung cancer ntrk gene fusionpositive solid first fdaapproved treatment designed target ntrk also shows response cancer spread june japanese ministry health labour welfare mhlw approved agent treatment adult pediatric patients ntrk advanced recurrent solid us food drug administration fda approved entrectinib based evidence four clinical trials patients various types solid tumors trial eudract trial trial trial trials conducted united states europe asiapacific fda granted entrectinib accelerated approval priority review breakthrough therapy orphan drug approval rozlytrek granted genentech process tumorigenesis frequently involves protein kinase activation events result either mutations chromosomal gene rearrangements leading expression constitutively activated fusion tyrosine kinase receptors increasingly identified common feature malignancies last three decades success demonstrated using rearrangements targets drug expression gene fusions tumor create phenomenon termed oncogene addiction tumor becomes dependent signaling aberrant kinase pathway thus rendering survival continued proliferation exquisitely sensitive targeted inhibition small molecule tyrosine kinase inhibitor expression proteins encoded tyrosine kinase fusion genes cases shown function independently oncogenic drivers capable activating critical downstream pathways involved malignant phenotype resulting transformation cells important kinases shown undergo rearrangement human cancers include anaplastic lymphoma kinase alk kinase neurotrophic receptor tyrosine kinases entrectinib selective tyrosine kinase inhibitor specificity low nanomolar concentrations three trk proteins encoded genes respectively well alk receptor tyrosine drug orally administered daily studiedwhen patients whose tumors shown fusions alk inhibitor entrectinib demonstrated cellular antiproliferative studies greater potency compared another commercially available inhibitor entrectinib also demonstrated invitro efficacy potential trk inhibitor resistance mutations entrectinib currentlywhen tested global phase ii basket clinical trial called interim results two ongoing phase trials reported aacr american association cancer research conference april among patients treated entrectinib four patients tumors harboring ntrk fusions including patients nonsmall cell lung cancer nsclc mcrc salivary gland cancer astrocytomacitation needed preliminary results seen entrectinib phase studies patients fusions led initiation openlabel multicenter global phase ii basket examine use entrectinib patients tumors gene rearrangements study enroll patient solid tumor evidence fusion assuming patient meets entry criteria examples tumor types include nsclc mcrc salivary gland cancer sarcoma melanoma thyroid cancer glioblastoma astrocytoma cholangiocarcinoma lymphoma otherscitation needed approved medical use united states august australia may investigations entrectinib conducted ignyta december roche announced plans buy ignyta entrectinib international nonproprietary name httpsenwikipediaorgwikientrectinib